Krystal Biotech, Inc.
KRYS
株式のランク
#2176
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
株価
$317.87
最終同期: 2026-10-16
時価総額
$9.41B
変化（1日）
-3.68%
変化（1年）
67.10%
国
US
取引 Krystal Biotech, Inc. (KRYS)
カテゴリー
Healthcare
Krystal Biotech, Inc.（KRYS）のEPS
June 2026 時点のEPS TTM: $8.27
Krystal Biotech, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$8.27です。2023年末には、EPSは$0.40で、2022年のEPS$-5.49と増加でした。
Krystal Biotech, Inc.のEPS履歴（2016から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $8.27 | 165.06% |
| 2024 | $3.12 | 680.00% |
| 2023 | $0.40 | -107.29% |
| 2022 | $-5.49 | 75.40% |
| 2021 | $-3.13 | 83.04% |
| 2020 | $-1.71 | 42.50% |
| 2019 | $-1.20 | 23.71% |
| 2018 | $-0.97 | -34.46% |
| 2017 | $-1.48 | 448.15% |
| 2016 | $-0.27 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | 109.43% |
US
|
|
| $-7.98 | -196.49% |
US
|
|
| $-5.29 | -163.97% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 235.43% |
NL
|
